• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcutis Biotherapeutics, Inc. - Common stock (NQ:ARQT)

25.16 -0.13 (-0.51%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,785,432
Open 25.64
Bid (Size) 25.14 (100)
Ask (Size) 25.17 (400)
Prev. Close 25.29
Today's Range 25.01 - 25.78
52wk Range 19.30 - 31.77
Shares Outstanding 50,241,789
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth and Improving Fundamentals ↗
October 01, 2026
Via Chartmill
News headline image
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
September 29, 2026
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire

Performance

52-Week Range 20.8% below 52-week high
25.16
19.3052W Low 31.7752W High
1 Week 9.0% below 1-week high
25.011W Low 27.641W High

Arcutis Biotherapeutics, Inc. - Common stock (ARQT) traded between $19.30 and $31.77 over the past 52 weeks and last traded at $25.16, 20.8% below its 52-week high. Over the past week it ranged between $25.01 and $27.64.

Past 12 Months
-7.9%
+6.3%
-3.5%
+6.4%
-13.2%
+26.3%
1W -$2.17
1M +$1.50
3M -$0.91
6M +$1.50
YTD -$3.84
1Y +$5.24

ARQT was +26.3% over the past year, +6.4% over six months, -13.2% year to date, -7.9% in the last week.

12 Months vs Market
ARQT
+26.3%
DIA
+9.3%
SPY
+15.0%
QQQ
+24.3%
IWM
+14.5%

Over the past 12 months ARQT returned +26.3% versus DIA (Dow) +9.3%, SPY (S&P 500) +15.0%, QQQ (Nasdaq 100) +24.3% and IWM (Russell 2000) +14.5%.

Volume & Liquidity 0.81× 3-mo avg
Today 1,785,432 3-mo avg 2.2M
1W
2.4M
1M
3.4M
3M
2.2M
6M
2.0M
YTD
1.8M
1Y
1.9M

ARQT most recently traded 1,785,432 shares against a 3-month average daily volume of 2.2M.

More News

Read More
Arcutis Biotherapeutics (NASDAQ:ARQT): Affordable Growth With Strong Upside Potential ↗
September 21, 2026
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): Strong Growth Meets a High-Quality Technical Setup ↗
September 19, 2026
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Delivers High Growth with Improving Fundamentals ↗
September 07, 2026
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): A Decent Value Stock With Growth Momentum ↗
August 24, 2026
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs High Growth Momentum with a Breakout Setup ↗
August 19, 2026
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Matches Navellier's Growth Playbook With Accelerating Fundamentals ↗
August 14, 2026
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Pairs Strong Growth with a Timely Technical Setup ↗
August 11, 2026
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT) Jumps on Q2 Beat and Raised Guidance ↗
August 05, 2026
Via Chartmill
News headline image
Arcutis (ARQT) Q2 2026 Earnings Call Transcript ↗
August 12, 2026
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Arcutis President and CEO Todd Watanabe Sells 4,375 Shares for $114,275 as Q2 Results Demonstrate Profitability ↗
August 06, 2026
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Arcutis Biotherapeutics Q2 Earnings Call Highlights ↗
August 05, 2026
Via MarketBeat
Topics Earnings
Arcutis Biotherapeutics (NASDAQ:ARQT) Shows High Growth Momentum and Breakout Setup ↗
July 23, 2026
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): An Affordable Growth Stock With Strong Revenue and Earnings Momentum ↗
July 20, 2026
Via Chartmill
Arcutis Biotherapeutics (NASDAQ:ARQT): High Growth Stock With a Strong Technical Setup ↗
July 17, 2026
Via Chartmill
News headline image
Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update
August 05, 2026
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Expands Board of Directors with Appointment of Chris Peetz
July 16, 2026
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
July 08, 2026
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis vs. Vertex: Which Pharmaceutical Maker Stock Is a Better Buy in 2026? ↗
July 03, 2026
Via The Motley Fool
Arcutis Director Sells $121,000 in Stock as ZORYVE Revenue Jumps 65% ↗
June 23, 2026
Via The Motley Fool
Arcutis Biotherapeutics Inc (NASDAQ:ARQT): A GARP Growth Play at a Reasonable Price ↗
June 22, 2026
Via Chartmill
News headline image
Arcutis Launches New Virtual Health Platform Supporting Access to Care for Individuals Living with Chronic Inflammatory Skin Diseases, Including Approved ZORYVE® (roflumilast) Indications
June 30, 2026
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Approves Arcutis’ ZORYVE® (roflumilast) Cream 0.3% for the Treatment of Plaque Psoriasis in Children as Young as Age 2
June 29, 2026
From Arcutis Biotherapeutics, Inc.
Via GlobeNewswire
News headline image
Arcutis Biotherapeutics Touts ZORYVE Growth, FDA Catalysts and Cash-Flow Positive Status ↗
June 09, 2026
Via MarketBeat

Frequently Asked Questions

Is Arcutis Biotherapeutics, Inc. - Common stock publicly traded?
Yes, Arcutis Biotherapeutics, Inc. - Common stock is publicly traded.
What exchange does Arcutis Biotherapeutics, Inc. - Common stock trade on?
Arcutis Biotherapeutics, Inc. - Common stock trades on the Nasdaq Stock Market
What is the ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock?
The ticker symbol for Arcutis Biotherapeutics, Inc. - Common stock is ARQT on the Nasdaq Stock Market
What is the current price of Arcutis Biotherapeutics, Inc. - Common stock?
The current price of Arcutis Biotherapeutics, Inc. - Common stock is 25.16
When was Arcutis Biotherapeutics, Inc. - Common stock last traded?
The last trade of Arcutis Biotherapeutics, Inc. - Common stock was at 10/02/26 04:00 PM ET
What is the market capitalization of Arcutis Biotherapeutics, Inc. - Common stock?
The market capitalization of Arcutis Biotherapeutics, Inc. - Common stock is 1.26B
How many shares of Arcutis Biotherapeutics, Inc. - Common stock are outstanding?
Arcutis Biotherapeutics, Inc. - Common stock has 1B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap